<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               14 CLINICAL STUDIES<BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.1	Metastatic Breast Cancer<BR>                     <BR>                        The randomized trial was a multicenter, double-blind, placebo-controlled trial of 808 patients with HER2-positive metastatic breast cancer.  Breast tumor specimens were required to show HER2 overexpression defined as 3+ IHC or FISH amplification ratio ≥ 2.0 determined at a central laboratory.  Patients were randomized 1:1 to receive placebo plus trastuzumab and docetaxel or PERJETA plus trastuzumab and docetaxel.  Randomization was stratified by prior treatment (prior or no prior adjuvant/neoadjuvant anti-HER2 therapy or chemotherapy) and geographic region (Europe, North America, South America, and Asia).  Patients with prior adjuvant or neoadjuvant therapy were required to have a disease-free interval of greater than 12 months before trial enrollment.<BR>                        PERJETA was given intravenously at an initial dose of 840 mg, followed by 420 mg every 3 weeks thereafter.  Trastuzumab was given intravenously at an initial dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks thereafter.  Patients were treated with PERJETA and trastuzumab until progression of disease, withdrawal of consent, or unacceptable toxicity.  Docetaxel was given as an initial dose of 75 mg/m2 by intravenous infusion every 3 weeks for at least 6 cycles.  The docetaxel dose could be escalated to 100 mg/m2 at the investigator's discretion if the initial dose was well tolerated.  At the time of the primary analysis, the mean number of cycles of study treatment administered was 16.2 in the placebo-treated group and 19.9 in the PERJETA-treated group.<BR>                        The primary endpoint of the randomized trial was progression-free survival (PFS) as assessed by an independent review facility (IRF).  PFS was defined as the time from the date of randomization to the date of disease progression or death (from any cause) if the death occurred within 18 weeks of the last tumor assessment.  Additional endpoints included overall survival (OS), PFS (investigator-assessed), objective response rate (ORR) and duration of response.<BR>                        Patient demographic and baseline characteristics were balanced between the treatment arms.  The median age was 54 (range 22 to 89 years), 59% were White, 32% were Asian, and 4% were Black.  All were women with the exception of 2 patients.  Seventeen percent of patients were enrolled in North America, 14% in South America, 38% in Europe, and 31% in Asia.  Tumor prognostic characteristics, including hormone receptor status (positive 48%, negative 50%), presence of visceral disease (78%) and non-visceral disease only (22%) were similar in the study arms.  Approximately half of the patients received prior adjuvant or neoadjuvant anti-HER2 therapy or chemotherapy (placebo 47%, PERJETA 46%).  Among patients with hormone receptor positive tumors, 45% received prior adjuvant hormonal therapy and 11% received hormonal therapy for metastatic disease.  Eleven percent of patients received prior adjuvant or neoadjuvant trastuzumab.<BR>                        The randomized trial demonstrated a statistically significant improvement in IRF-assessed PFS in the PERJETA-treated group compared with the placebo-treated group [hazard ratio (HR) = 0.62 (95% CI:  0.51, 0.75), p < 0.0001] and an increase in median PFS of 6.1 months (median PFS of 18.5 months in the PERJETA-treated group vs. 12.4 months in the placebo-treated group) (see Figure 1).  The results for investigator-assessed PFS were comparable to those observed for IRF-assessed PFS.<BR>                        Consistent results were observed across several patient subgroups including age (< 65 or ≥ 65 years), race, geographic region, prior adjuvant/neoadjuvant anti-HER2 therapy or chemotherapy (yes or no), and prior adjuvant/neoadjuvant trastuzumab (yes or no).  In the subgroup of patients with hormone receptor-negative disease (n=408), the hazard ratio was 0.55 (95% CI: 0.42, 0.72).  In the subgroup of patients with hormone receptor-positive disease (n=388), the hazard ratio was 0.72 (95% CI: 0.55, 0.95).  In the subgroup of patients with disease limited to non-visceral metastasis (n=178), the hazard ratio was 0.96 (95% CI: 0.61, 1.52).<BR>                        At the time of the PFS analysis, 165 patients had died.  More deaths occurred in the placebo-treated group (23.6%) compared with the PERJETA-treated group (17.2%).  At the interim OS analysis, the results were not mature and did not meet the pre-specified stopping boundary for statistical significance.  See Table 2 and Figure 2.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="100%" ID="table2"><BR>                           <caption>Table 2	Summary of Efficacy from the Randomized Trial</caption><BR>                           <col width="35%" align="left" valign="bottom"/><BR>                           <col width="20%" align="center" valign="bottom"/><BR>                           <col width="20%" align="center" valign="bottom"/><BR>                           <col width="15%" align="center" valign="bottom"/><BR>                           <col width="10%" align="center" valign="bottom"/><BR>                           <thead><BR>                              <tr><BR>                                 <th styleCode="Lrule Rrule"/><BR>                                 <th styleCode="Rrule">PERJETA + trastuzumab + docetaxel</th><BR>                                 <th styleCode="Rrule">Placebo + trastuzumab + docetaxel</th><BR>                                 <th styleCode="Rrule">HR</th><BR>                                 <th styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <th styleCode="Lrule Rrule" align="center">Parameter</th><BR>                                 <th styleCode="Rrule">n=402</th><BR>                                 <th styleCode="Rrule">n=406</th><BR>                                 <th styleCode="Rrule">(95% CI)</th><BR>                                 <th styleCode="Rrule">p-value</th><BR>                              </tr><BR>                           </thead><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Progression-Free Survival</content><BR>                                 </td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">(independent review)</content><BR>                                 </td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule">0.62</td><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule">&lt; 0.0001</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule">(0.51, 0.75)</td><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">No. of patients with an event</content><BR>                                 </td><BR>                                 <td styleCode="Rrule">191 (47.5%)</td><BR>                                 <td styleCode="Rrule">242 (59.6%)</td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Median months</content><BR>                                 </td><BR>                                 <td styleCode="Rrule">18.5</td><BR>                                 <td styleCode="Rrule">12.4</td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Overall Survival</content><BR>                                 </td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">(interim analysis)</content><BR>                                 </td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule">0.64</td><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule">0.0053<footnote>The HR and p-value for the interim analysis of Overall Survival did not meet the pre-defined stopping boundary (HR &#8804; 0.603, p &#8804; 0.0012).</footnote><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule">(0.47, 0.88)</td><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">No. of patients with an event</content><BR>                                 </td><BR>                                 <td styleCode="Rrule">69 (17.2%)</td><BR>                                 <td styleCode="Rrule">96 (23.6%)</td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Objective Response Rate (ORR)</content><BR>                                 </td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">No. of patients analyzed</content><BR>                                 </td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Objective response (CR + PR)</td><BR>                                 <td styleCode="Rrule">343</td><BR>                                 <td styleCode="Rrule">336</td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Complete response (CR)</td><BR>                                 <td styleCode="Rrule">275 (80.2%)</td><BR>                                 <td styleCode="Rrule">233 (69.3%)</td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Partial Response (PR)</td><BR>                                 <td styleCode="Rrule">19 (5.5%)</td><BR>                                 <td styleCode="Rrule">14 (4.2%)</td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"/><BR>                                 <td styleCode="Rrule">256 (74.6%)</td><BR>                                 <td styleCode="Rrule">219 (65.2%)</td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Median Duration of Response (months)</td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"/><BR>                                 <td styleCode="Rrule">20.2</td><BR>                                 <td styleCode="Rrule">12.5</td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="100%" styleCode="Noautorules" ID="figure1"><BR>                           <col width="100%" align="center" valign="middle"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Figure 1	Kaplan-Meier Curve of IRF-Assessed Progression-Free Survival for the Randomized Trial</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <renderMultiMedia referencedObject="MM1"/><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="100%" styleCode="Noautorules" ID="figure2"><BR>                           <col width="100%" align="center" valign="middle"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Figure 2	Kaplan-Meier Curve of Overall Survival for the Randomized Trial</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <renderMultiMedia referencedObject="MM2"/><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                     <BR><BR><BR><BR>                     <BR>                     <BR>                        <BR>                           Figure 1<BR>                           <BR>                              <BR>                           <BR>                        <BR>                     <BR>                     <BR>                        <BR>                           Figure 2<BR>                           <BR>                              <BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>